A.L.I.V.E™
Left ventricular devices are machines designed to assist the ventricle of the heart to perform its function. Most LVADs require oxygenated blood to be diverted from the left ventricle and routed to the aortic arch region. This procedure requires a surgery that takes nearly twice as long, as it require two points of connection to attach the machine to the native heart & vessel. It is common knowledge that prolonged & complex surgery often results in greater risk of morbidity and mortality.
Moreover LVADs may be associated with other inherent shortcomings such as hemolysis of red blood cells, resulting in one form of anemia in patients who are heavily dependent on healthy blood cells. The hemolysis is often caused by the pump mechanism that operates like a propeller, spinning at more than 1000 rpm. With such mechanism, a pulse is also noticeably absent. The apparatus as described also requires enormous amounts of energy to operate, limiting the patient’s mobility and freedom.
Parace Bionics, LLC is pioneering a patent pending technology to overcome all of the shortcomings of most LVADs. Most noticeably our leap frog technology will generate a current during its operation, prolonging its operation, reducing battery size & frequency of recharging. A.L.I.V.E.™ is both a pump and a generator, creating electricity from a novel approach. Moreover, the LVAD technology will incorporate the use of a revolutionary battery system, that will last more than 2x longer than conventional Li batteries.
This is the first cardiac technology in the world to perform this “game changing” feat. Further, the patient’s blood will never leave the circulatory system, thereby reducing contact of a patient’s blood with alien material, which will reduce the risk of thrombus significantly. Another clear benefit is maintaining a pulse that mimics a patient’s natural heart beat.
The company is committed to developing this technology in the United States (Made in America) using Federal funding and partnership with visionary leaders in Ohio, which has the largest bioscience sector in the Midwest.
